Home › Compare › EQRXW vs GBDC

EQRXW vs GBDC: Dividend Comparison 2026

EQRXW yields 4395.60% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EQRXW wins by $17844003331669.19M in total portfolio value
10 years
EQRXW
EQRXW
● Live price
4395.60%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$17844003331690.04M
Annual income
$17,079,643,292,413,290,000.00
Full EQRXW calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — EQRXW vs GBDC

📍 EQRXW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEQRXWGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EQRXW + GBDC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
EQRXW pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EQRXW
Annual income on $10K today (after 15% tax)
$373,626.37/yr
After 10yr DRIP, annual income (after tax)
$14,517,696,798,551,296,000.00/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, EQRXW beats the other by $14,517,696,798,537,312,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EQRXW + GBDC for your $10,000?

EQRXW: 50%GBDC: 50%
100% GBDC50/50100% EQRXW
Portfolio after 10yr
$8922001665855.45M
Annual income
$8,539,821,646,214,871,000.00/yr
Blended yield
95.72%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

EQRXW
No analyst data
Altman Z
9.5
Piotroski
1/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EQRXW buys
0
GBDC buys
0
No recent congressional trades found for EQRXW or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEQRXWGBDC
Forward yield4395.60% ✓11.86%
Annual dividend / share$2.00 ✓$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1% ✓
Portfolio after 10y$17844003331690.04M ✓$20.85M
Annual income after 10y$17,079,643,292,413,290,000.00 ✓$16,450,733.83
Total dividends collected$17792054110403.60M ✓$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: EQRXW vs GBDC ($10,000, DRIP)

YearEQRXW PortfolioEQRXW Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$450,260$439,560.44$12,492$1,791.70+$437.8K → EQRXW
2$18,978,664$18,496,885.68$16,527$3,160.58+$18.96M → EQRXW
3$748,953,345$728,646,173.66$23,588$5,904.90+$748.93M → EQRXW
4$27,674,743,815$26,873,363,736.79$37,141$11,901.65+$27674.71M → EQRXW
5$957,652,835,286$928,040,859,403.20$66,205$26,463.38+$957652.77M → EQRXW
6$31,037,578,041,538$30,012,889,507,782.54$137,452$66,612.65+$31037577.90M → EQRXW
7$942,293,671,101,243$909,083,462,596,797.50$342,372$195,298.53+$942293670.76M → EQRXW
8$26,802,238,424,024,828$25,793,984,195,946,500.00$1,053,292$686,954.33+$26802238422.97M → EQRXW
9$714,355,176,894,161,700$685,676,781,780,455,000.00$4,111,439$2,984,416.95+$714355176890.05M → EQRXW
10$17,844,003,331,690,041,000$17,079,643,292,413,290,000.00$20,849,974$16,450,733.83+$17844003331669.19M → EQRXW

EQRXW vs GBDC: Complete Analysis 2026

EQRXW — Stock

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. Its product pipeline in development includes Aumolertinib, an EGFR inhibitor for the treatment of ?EGFR-mutated? non-small cell lung cancer (NSCLC); Sugemalimab, an anti-PD-L1 antibody for the treatment of ?stage III and IV ?NSCLC; Lerociclib, a CDK4/6 inhibitor to treat HR+/HER2- breast cancer; and EQ176, an anti-PD-1?antibody for the treatment of liver cancer. The company has partnerships with Exscientia and AbCellera Biologics Inc. EQRx, Inc. was founded in 2020 and is based in Cambridge, Massachusetts.

Full EQRXW Calculator →

GBDC — BDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this EQRXW vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EQRXW vs SCHDEQRXW vs JEPIEQRXW vs OEQRXW vs KOEQRXW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.